Xuquan Jing
Overview
Explore the profile of Xuquan Jing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niu J, Jing X, Xu Q, Liu H, Tian Y, Yang Z, et al.
Future Oncol
. 2024 Aug;
20(32):2481-2490.
PMID: 39155845
In first/second generation EGFR-TKIs, strong PD-L1 expression contributes to primary resistance, significantly affecting patient prognosis. The relationship between PD-L1 expression levels and third-generation TKIs remains unclear. This study analyzed advanced...
2.
Wang M, Jing X, Chen F, Lu S, Sun Y
BMC Cancer
. 2024 May;
24(1):569.
PMID: 38714983
Background: No definite conclusion has yet to be reached for immunotherapy beyond progression(IBP) of first-line immunotherapy as the second-line treatment for advanced NSCLC patients with negative driver genes. Therefore a...
3.
Lu S, Guo X, Yang Z, Sun Y, Niu J, Jing X, et al.
Future Oncol
. 2024 Apr;
:1-14.
PMID: 38591950
This study assesses immune checkpoint inhibitors' efficacy for non-small-cell lung cancer (NSCLC) with brain metastases (BM) and explores the role of cranial radiation therapy (CRT) in the immunotherapy era. The...
4.
Jia W, Zhai X, Jing X, Bao Q, Xu S, Zhu H, et al.
J Neurooncol
. 2023 Aug;
164(2):321-330.
PMID: 37648933
Purpose: The updated Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (lung-molGPA) index provide more accurate survival prediction for patients diagnose with advanced non-small cell lung cancer (NSCLC) with...
5.
Li Y, Jing W, Jing X, Sun Y, Tang X, Guo J, et al.
Discov Oncol
. 2023 May;
14(1):55.
PMID: 37142872
Objective: To investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance. Patients And Methods: Outcomes of patients without...
6.
Jing X, Zhu H, Li Y, Jia W, Zhai X, Li J, et al.
Immunotherapy
. 2022 Sep;
14(14):1097-1107.
PMID: 36093721
A standard treatment for advanced thymic epithelial tumors (TETs) after initial treatment remains unavailable to date. Targeted immune checkpoint inhibitors (ICIs) of the programmed cell death-1 (PD-1) pathway may produce...
7.
Chang J, Jing X, Hua Y, Geng K, Li R, Lu S, et al.
J Cancer Res Clin Oncol
. 2022 Jun;
149(5):1825-1833.
PMID: 35737093
Purpose: The objective of this study was to evaluate the safety and efficacy of immune checkpoint inhibitors in small cell lung cancer patients with brain metastases. Methods: We retrospectively reviewed...
8.
Zhu H, Jia W, Jing X, Huang W, Wang L, Yu J
JTO Clin Res Rep
. 2022 Jun;
3(6):100339.
PMID: 35663415
Introduction: Anlotinib has brought about marked progression-free survival and overall survival benefit compared with placebos as third-line or further treatment in advanced NSCLC. Nevertheless, the safety and efficacy of concurrent...
9.
Tian Y, Ma J, Jing X, Zhai X, Li Y, Guo Z, et al.
Cancer Lett
. 2022 May;
541:215719.
PMID: 35597478
Unlike non-small-cell lung cancer (NSCLC), the progression of small-cell lung cancer (SCLC) is slow. Extensive-stage SCLC (ES-SCLC) is a serious threat to human health, with a 5-year survival rate of...
10.
Zhai X, Jing X, Li J, Tian Y, Xu S, Wang M, et al.
Front Oncol
. 2020 Oct;
10:556275.
PMID: 33102221
Background: Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor monotherapy has been approved as second-line or later therapy in advanced non-small-cell lung cancer (NSCLC). The study aimed to compare the clinical...